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Received January 10, 2013; accepted April 22, 2013AbstractBackground: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective against tumor EGFR-mutated non-small
cell lung cancer (NSCLC). Patients with the tumor EGFR-activating mutation (EGFRmu) had superior survival, compared to patients with
EGFR wild-type tumors (EGFRwt). Many patients with the EGFRmu have had disease progression with EGFR-TKI treatment because of central
nervous system (CNS) metastases. The objective of this retrospective study was to compare the causes of death in patients with a known tumor
EGFR mutation status who had been treated with EGFR-TKIs.
Methods: We retrospectively reviewed the chart records of our patients with advanced NSCLC who had received diagnosis, treatment, and
supportive and hospice care in our hospital between July 2005 and June 2010. The tumor EGFR mutation status was analyzed by using a DNA
sequence method. All enrolled patients had a documented cause of death.
Results: Ninety-four patients had documented tumor EGFR data, had received EGFR-TKI treatment (either erlotinib or gefitinib), and were with
or without previous or salvage systemic chemotherapy. Of the 94 patients, 36 patients had EGFRwt and 58 patients had EGFRmu. The overall
patient survival after starting EGFR-TKI treatment was significantly longer in the EGFRmu patients (median 17.2 months) than in the EGFRwt
patients (median 11.6 months; p ¼ 0.0058). Twenty-nine patients died of CNS metastases and 65 died of organ failure (other than the CNS).
Patients who died of CNS metastases had undergone EGFR-TKI treatment significantly longer than patients who died of other organ failure
(median, 8 months vs. 1.9 months; p ¼ 0.0003) with a hazard ratio of 2.308 [95% confidence interval (C.I.), 1.452e3.668; p ¼ 0.0004]. A
significantly higher proportion of EGFRmu patients (26 of 58 patients; 44.8%) than EGFRwt patients (3 of 36 patients; 8.3%) ( p < 0.001) died
of CNS metastases.
Conclusion: The EGFRmu NSCLC patients survived longer and had a significantly higher probability of mortality due to CNS metastases,
compared to the EGFRwt patients. This change in the causes of death was noted after the era of EGFR-TKI treatment, and will have an important
impact on the strategies and management of supportive and hospice care for patients.
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Lung cancer is the leading cause of cancer mortality
worldwide. Only a few patients with lung cancer present with
early-stage disease that is suitable for surgical treatment. Most
patients are diagnosed with metastatic and advanced disease
and have a dismal prognosis that seldom reaches beyond 1e2hinese Medical Association. All rights reserved.
Table 1
Clinical characteristics of the 94 patients.
Patients with
EGFRmua
Patients with
EGFRwt
Total
Patient, n (%) 58 (61.7) 36 (38.3) 94
Sex
Male 25 17 42
Female 33 19 52
Age, mean (range) 60.8 (32e85) 60.1 (36e87) 60.5 (32e87)
Median duration of
EGFR-TKI treatment,
mo. (range)
6.5 (0.1e35.1) 1.4 (0.2e9.9) 3.2 (0.1e35.1)
Median survival time,
mo. (range)
17.2 (0.5e78.5) 11.6 (1.6e47.6) 15.3 (0.5e78.5)
Cause of death
CNS metastasis 26 3 29
Non-CNS metastasis 32 33 65
CNS ¼ central nervous system; EGFR ¼ epidermal growth factor receptor;
EGFRmu ¼ EGFR-activating mutation; EGFRwt ¼ EGFR wild-type tumor;
TKI ¼ tyrosine kinase inhibitor.
a Includes 36 patients with exon 19 deletions and 22 patients with exon 21
L858R.
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a response rate of 20e35% and a median survival time of
10e12 months among patients with advanced non-small cell
lung cancer (NSCLC).1,2 The epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKIs) improve the
survival of lung cancer patients as a second-line or third-line
therapy. A selective patient profile that included female
gender, nonsmoker or light smoker, East Asian ethnicity, and
adenocarcinoma was more beneficial than other profiles.3
Pooled analyses in different areas suggest particularly prom-
ising results with EGFR-TKI therapy among patients
harboring EGFR mutations.4,5 The discovery of a mutation in
the tyrosine kinase domain of the EGFR in NSCLC represents
a dramatic step in developing a treatment strategy for lung
cancer. Large-scale screenings for EGFR mutations have had a
great influence on decision-making in regard to treatment.6
Recently reported prospective trials further define the role of
EGFR-TKIs as a first-line therapy.7,8 Patients with a tumor
with a EGFR-activating mutation (EGFRmu; i.e., exon 19
deletions or exon 21 L958R) had better survival than patients
with EGFR wild-type tumors (EGFRwt).4,9 The optimal use of
EGFR-TKIs to prolong the survival of patients with NSCLC is
gradually coming into focus.
An increased risk of central nervous system (CNS)
metastasis such as leptomeningeal carcinomatosis (LM) has
been reported among patients who achieved disease control
with gefitinib or erlotinib.10e12 This has changed the cause of
mortality from lung cancer, which was previously character-
ized primarily as respiratory failure. The purpose of this study
was to evaluate the influence of EGFR-TKIs on the cause of
death in patients with advanced NSCLC whose tumor EGFR
mutation status is known and who were treated with EGFR-
TKI.
2. Methods
We retrospectively reviewed the chart records of our pa-
tients with advanced NSCLC who had received diagnosis,
treatment, supportive care, and hospice care in our hospital
between July 2005 and June 2010. This study was approved by
our Institutional Review Board (VGHIRB 2011-04-0151A).
The patients were all documented as deceased prior to our data
review. The tumor EGFR mutation status was analyzed by
using a DNA sequence method. Lung cancer staging was
evaluated in accordance with the sixth edition of the tumor
node metastasis staging system for NSCLC (AJCC Cancer
Staging Manual 6th edition; Chapter 19; p. 167e77).
Analysis for the EGFR mutation was performed with
nucleotide sequence analysis. The VariantSEQr Resequencing
Primer Set (Life Technologies CO., Ltd., New York, USA)
was selected for the mutational analysis of the tyrosine kinase
domain and exons 18e21 of the EGFR gene. Genomic DNA
was extracted from paraffin blocks, exons 18e21 were
amplified, and uncloned polymerase chain reaction fragments
were sequenced and analyzed (in the sense and antisense di-
rections) for the presence of heterozygous mutations. Normal
control DNA provided by the ABI Company (Columbia, MD,USA) was used for the wild-type control. All sequence vari-
ations were confirmed by multiple independent polymerase
chain reaction amplifications and repeated sequencing re-
actions. The EGFR-activating mutations were defined as mu-
tations with exon 19 deletions or exon 21 L858R.
Survival was measured from the date of initiating EGFR-
TKI treatment (with erlotinib or gefitinib) to the date of
death or last follow-up examination. A CNS death was
attributed to CNS progression, which resulted in the worsening
of neurological symptoms. Extracranial diseases were in a
stable condition, according to the medical records. Death un-
related to CNS metastases was attributed to extracranial me-
tastases that caused a target organ failure-related death.
The Kaplan-Meier method with a log-rank test and the Cox
proportional hazard model were used for statistical analysis of
survival. All statistical analyses were performed by using
SPSS software (version 19) (SPSS Inc., Chicago, IL, USA).3. Results
Ninety-four patients had documented tumor EGFR data,
had received EGFR-TKI treatment, and were with or without
previous or salvage chemotherapy. All patients were deceased
prior to our data review. Of this group, 36 had EGFRwt and 58
had EGFRmu; 42 patients were male and 52 were female. The
mean age of the entire study population was 60.5 years.
Thirty-six (62%) patients had an exon 19 deletion and 22
(38%) patients had exon 21 L858R point mutations. Of the
patients with EGFRmu who died of CNS metastases, 17
(65.3%) patients had additional LM detected by brain MRI
examinations. All three (100%) patients with EGFRwt who
died of CNS metastases also had LM. Table 1 shows the
clinical characteristics of the patients.
The overall survival after starting EGFR-TKI treatment was
significantly longer for patients with the EGFRmu than for
Fig. 1. The survival curve of all 94 patients who received EGFR-TKI with and
without EGFR mutation (median 17.2 months vs. 11.6 months; p ¼ 0.0058).
684 W.-S. Wu et al. / Journal of the Chinese Medical Association 76 (2013) 682e685patients with EGFRwt (median, 17.2 months vs. 11.6 months,
respectively; p ¼ 0.0058; Fig. 1). Twenty-nine patients died
of CNS metastases and 65 patients died of organ failure
(other than the CNS). Patients who died of CNS metastases
had received EGFR-TKI treatment significantly longer than
patients who died of other organ failure (median 8 months vs.
1.9 months, respectively; p ¼ 0.0003) with a hazard ratio of
2.308 (95% C.I. 1.452e3.668; p ¼ 0.0004). Only 3 of the 36
patients with EGFRwt died of CNS metastases. A significantly
higher proportion of EGFRmu patients (26 of 58; 44.8%) died
of CNS metastases, compared to EGFRwt patients (3 of 36;
8.3%; p < 0.001).4. Discussion
According to our results, patients with the EGFRmu who
received EGFR-TKI treatment had a longer survival compared
to patients with EGFRwt who received the same treatment.
The cause of mortality was also different between patients
with EGFRmu and patients with EGFRwt. The CNS is a
frequent site of disease progression or recurrence in patients
with NSCLC, even in patients who are responsive to EGFR-
TKI treatment such as gefitinib.10 This is a major problem
during the terminal stage of NSCLC because of the severe
impact on the patients’ quality of life.13 LM, one manifesta-
tion of CNS metastasis, is a difficult disease to treat. In the
literature, major favorable prognostic factors of LM include a
good Eastern Cooperative Oncology performance status, the
absence of serious fixed neurologic deficits, normal cerebro-
spinal fluid flow scans, and absent or responsive systemic
disease.14 Management options for LM, other than palliative
measures, are limited and include intrathecal chemotherapy orwhole brain and/or spinal axis irradiation, all of which usually
do not prolong patient survival.15e17
The high incidence of CNS metastases in EGFR-TKI-
treated EGFRmu patients may be caused by the incom-
plete penetration of TKI into the CNS; this may result in
brain metastases or even LM.18,19 Several studies demon-
strate that the concentration of gefitinib was low in the CNS,
when using the standard dose treatment.18,19 Increasing the
dose of gefitinib in a subset of EGFRmu NSCLC patients
can treat or prevent metastatic CNS disease.19 Other studies
also report favorable results for gefitinib-treated patients
with CNS progression that was salvaged with erlotinib
treatment, probably because of the higher serum erlotinib
concentrations and better CSF penetration than with
gefitinib.18,20
When patients experience disease progression with CNS
metastasis or LM, they frequently suffer from headache,
vomiting, memory loss, seizures, multiple neurological and
sensory impairments such as diplopia, tinnitus, vertigo,
hearing impairment; and vision loss. They finally became
comatose. Higher doses or pulse therapy with EGFR-TKI
has been tried20 and intrathecal chemotherapy has been
tried for meningeal carcinomatosis.17,21,22 Whole brain ra-
diation therapy also plays an important role in treating this
kind of patient. However, the absolute benefit of whole brain
radiotherapy for patients in the terminal stage of NSCLC
who have CNS failure remains undetermined.16,22,23 Medical
treatments with steroid and glycerol may also have only
short-term effects. Patients with LM or hydrocephalus
sometimes may need cerebrospinal fluid drainage for intra-
cranial pressure release.
Patients who died of extra-CNS failure died primarily
because of respiratory failure. Profound metastasis in the lung
parenchyma, central airway obstruction, and severe hemop-
tysis may lead to respiratory failure. Some palliative therapy
regimens can be administered to relieve symptoms with the
objective of enhancing the quality of life of patients in the
terminal stage of lung cancer. Repeated drainage with thor-
acentesis or pleurodesis may be helpful in improving symp-
toms in patients with massive effusion or symptomatic pleural
effusion.24,25 Malignant pericardial effusion is also a detri-
mental condition that may develop into cardiac tamponade.
Urgent intervention is consequently required to provide rapid
relief of symptoms. Severe bone pain, visceral pain, or neu-
ropathy may have a great impact on a patient’s quality of life.
Opioids are useful and safe medications for terminally ill
patients who experience severe pain and dyspnea during their
last days.26
It has been suggested that integrating palliative care with
standard oncologic care earlier in the management of patients
with advanced lung cancer improves the quality of life and
mood.27,28 The change in the causes of death after an era of
EGFR-TKI treatment will impact the strategies and manage-
ment of supportive and hospice care for patients. A multidis-
ciplinary approach for the palliative care needs of patients
with CNS metastases is becoming more apparent and neces-
sary as each new day passes.
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